Please assess the completion status of the following clinical trial:

Trial Title: Ulipristal Emergency Contraception Used Before or After Ovulation

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Healthy women aged 18 years or above;~2. Regular menstrual cycles (every 21-35 days) within the past three cycles;~3. Requesting emergency contraception within 120 h of a single act of unprotected intercourse in the current menstrual cycle;~4. Willing to abstain from further acts of unprotected intercourse and;~5. Available for follow-up over the next 6 weeks~Exclusion Criteria:~1. Post-abortion or postpartum patients whose period had not yet returned~2. Regular use of prescription drugs before admission to the study and~3. Intercourse during the treatment cycle more than 120 h before admission into the study.~4. Found pregnant at the time of presentation~5. Breastfeeding women~6. Women who have been sterilized (or partner being sterilized) or have intrauterine contraceptive device in-situ~7. Uncertain about the date of the last menstrual period~8. Women who had used hormonal contraceptive in the current or past one cycle

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pre-ovulatory (Type: None): Ulipristal acetate 30 mg single oral dose
- Post-ovulatory (Type: None): Ulipristal acetate 30 mg single oral dose

Based on this trial design, predict the completion outcome and termination type (if applicable).